Connect with us

News

Co-Diagnostics Announces $4.2 Million Registered Direct Offering Priced At-the-Market

gbafNews28

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into definitive agreements with institutional investors for the purchase of 470,000 shares of its common stock, at a purchase price of $9.00 per share, in a registered direct offering priced at-the-marked under the Nasdaq rules. The closing of the offering is expected to occur on or about March 2, 2020, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive lead placement agent for the offering. Maxim Group LLC is acting as co-placement agent.

The gross proceeds to the Company, before deducting placement agent fees and other offering expenses, are expected to be approximately $4.2 million. Co-Diagnostics intends to use the net proceeds from this offering for acquisition of PCR (polymerase chain reaction) equipment and raw materials to be used in connection with sale of tests used to diagnose infectious disease, including strains and mutations of coronavirus, as well as research and development costs associated with test development for additional pathogens and test menu expansion, and for working capital and other general corporate purposes.

The shares of common stock are being offered by Co-Diagnostics pursuant to a “shelf” registration statement on Form S-3 that was originally filed on August 14, 2018 and declared effective by the Securities and Exchange Commission (“SEC”) on September 7, 2018, and the base prospectus contained therein (File No. 333-226835). The offering of the shares of common stock will be made only by means of a prospectus supplement that forms a part of the registration statement.

A final prospectus supplement and accompanying base prospectus relating to the shares of common stock being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying base prospectus may be obtained, when available, on the SECs website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at [email protected].

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Companys technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Companys products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Companys balance sheet, (vii) anticipation of business expansion, (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages and (ix) statements regarding the offering, the expected gross proceeds from the offering, the intended use of proceeds and the timing of the closing of the offering. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances, including market conditions. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Andrew Benson

Co-Diagnostics Investor Relations

801-438-1036

[email protected]

News

WeissLaw LLP Reminds IPHI, EMIS, and EIDX Shareholders About Its Ongoing Investigations

gbafNews28

NEW YORK, Dec. 4, 2020 /PRNewswire/ —

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
[email protected]

Inphi Corporation (NASDAQ: IPHI)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Inphi Corporation (NASDAQ: IPHI) in connection with the company's proposed mixed cash-and-stock merger with Marvell Technology Group Ltd. (“MRVL”). Under the terms of the merger agreement, IPHI shareholders will receive $66.00 in cash and 2.323 shares of the newly-combined company for each IPHI share that they own. If you own IPHI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/iphi/

Emisphere Technologies Inc. (OTCM: EMIS)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Emisphere Technologies, Inc. (OTCM: EMIS) in connection with the proposed merger of the Company with Novo Nordisk A/S (“Novo”). Under the terms of the agreement, EMIS stockholders are expected to receive approximately $7.82 for each share of EMIS common stock that they hold. Novo also entered into an agreement to acquire related royalty stream obligations owed to affiliates of MHR Fund Management LLC (“MHR”) for $450 million. The investigation is focused on whether (i) the special committee of EMIS' board acted in the best interest of EMIS's minority shareholders in agreeing to the transaction, (ii) the consideration adequately compensates EMIS' minority shareholders, and (iii) all information regarding the transaction will be fully and fairly disclosed, in light of the fact that the majority of EMIS' shares are controlled by MHR and the EMIS board and MHR cashing out its' royalty stream interests. If you own EMIS shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/EMIS/

Eidos Therapeutics, Inc. (NASDAQ: EIDX)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Eidos Therapeutics, Inc. (NASDAQ: EIDX) in connection with the proposed interested-party acquisition of the company by BridgeBio Pharma, Inc. (“BridgeBio”). Under the terms of the acquisition agreement, EIDX shareholders can elect to receive either 1.85 shares of BridgeBio or $73.26 for each share of EIDX common stock that they own, subject to proration such that the aggregate cash portion will not exceed $175 million. If you own EIDX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/eidx/

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/weisslaw-llp-reminds-iphi-emis-and-eidx-shareholders-about-its-ongoing-investigations-301186794.html

SOURCE WeissLaw LLP

Continue Reading

News

SHAREHOLDER ALERT: WeissLaw LLP Reminds ROCH, TOTA, and DMYD Shareholders About Its Ongoing Investigations

gbafNews28

NEW YORK, Dec. 4, 2020 /PRNewswire/ —

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
[email protected]

Roth CH Acquisition I Co. (NASDAQ: ROCH)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Roth CH Acquisition I Co. (NASDAQ: ROCH) in connection with the Company's proposed merger with PureCycle Technologies LLC (“PureCycle”), a privately-held plastics recycling company. Under the terms of the merger agreement, ROCH will acquire PureCycle through a reverse merger that will result in PureCycle becoming a public company traded on the Nasdaq Capital Market under the new ticker symbol “PCT.” The transaction has an implied enterprise value of approximately $826 million. If you own ROCH shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/roch/

Tottenham Acquisition I Limited (NASDAQ: TOTA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tottenham Acquisition I Limited (NASDAQ: TOTA) in connection with the company's proposed merger with privately-held clinical-stage biopharmaceutical company, Clene Nanomedicine, Inc. (“Clene”). Under the terms of the merger agreement, TOTA will acquire Clene through a reverse merger that will result in Clene becoming a public company listed on the Nasdaq Capital Market. The proposed transaction values Clene at $542.5 million. If you own TOTA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/tottenham-acquisition-i-limited/

dMY Technology Group, Inc. II (NYSE: DMYD)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of dMY Technology Group, Inc. II (NYSE: DMYD) in connection with the company's proposed merger with Genius Sports Group Limited (“GSG”). Under the terms of the agreement, DMYD will acquire GSG through a reverse merger that will result in GSG becoming a public company. If you own DMYD shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/dmyd/

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-roch-tota-and-dmyd-shareholders-about-its-ongoing-investigations-301186793.html

SOURCE WeissLaw LLP

Continue Reading

News

SHAREHOLDER ALERT: WeissLaw LLP Investigates Star Peak Energy Transition Corp.

gbafNews28

NEW YORK, Dec. 4, 2020 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Star Peak Energy Transition Corp. (“STPK” or the “Company”) (NYSE: STPK) in connection with the Company's proposed merger with Stem Inc. (“Stem”), a privately-held artificial intelligence-driven energy storage company. Under the terms of the merger agreement, STPK will acquire Stem through a reverse merger that will result in Stem becoming a public company, traded on the New York Stock Exchange under the ticker symbol “STEM.” The transaction values the combined company at approximately $1.35 billion.

If you own STPK shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslawllp.com/STPK/

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw is investigating whether STPK's board acted in the best interest of STPK's public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of Stem, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to STPK public shareholders.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected].

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-star-peak-energy-transition-corp-301186790.html

SOURCE WeissLaw LLP

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News45 mins ago

Pomerantz Law Firm Announces the Filing of a Class Action against Boston Scientific Corporation and Certain Officers – BSX

NEW YORK, Dec. 4, 2020 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Boston...

gbafNews28 gbafNews28
News45 mins ago

AB Staffing Solutions, LLC Provides Notice Of Data Privacy Event

GILBERT, Ariz., Dec. 4, 2020 /PRNewswire/ — AB Staffing Solutions, LLC (“AB Staffing”) provides notice of a recent incident that may...

gbafNews28 gbafNews28
News45 mins ago

2020 California Economic Summit Launches the California Dream Index and Fortifies Action Plans for an Equitable and Inclusive Economic Recovery

SACRAMENTO, Calif., Dec. 4, 2020 /PRNewswire/ — The 2020 California Economic Summit concluded virtually today, marking the ninth gathering of more...

gbafNews28 gbafNews28
News45 mins ago

WeissLaw LLP Reminds TGC, APXT, FSKR, and INAQ Shareholders About Its Ongoing Investigations

NEW YORK, Dec. 4, 2020 /PRNewswire/ — If you own shares in any of the companies listed above and would...

gbafNews28 gbafNews28
News45 mins ago

SHAREHOLDER ALERT: WeissLaw LLP Investigates Star Peak Energy Transition Corp.

NEW YORK, Dec. 4, 2020 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law...

gbafNews28 gbafNews28
News45 mins ago

SHAREHOLDER ALERT: WeissLaw LLP Reminds ROCH, TOTA, and DMYD Shareholders About Its Ongoing Investigations

NEW YORK, Dec. 4, 2020 /PRNewswire/ — If you own shares in any of the companies listed above and would...

gbafNews28 gbafNews28
News45 mins ago

WeissLaw LLP Reminds IPHI, EMIS, and EIDX Shareholders About Its Ongoing Investigations

NEW YORK, Dec. 4, 2020 /PRNewswire/ — If you own shares in any of the companies listed above and would...

gbafNews28 gbafNews28
News47 mins ago

2021 skincare solutions just a click away with POND’S Skin Advisor Live chatbot now on Shopee

Banish Pandemic-induced Skincare Woes with POND’s Beauty Tech on Shopee   HO CHI MINH CITY, VIETNAM – Media OutReach – 1 December...

gbafNews28 gbafNews28
News47 mins ago

Consumer spending in Islamic economy sectors forecast to rebound by end-2021, market size slated to reach US$2.3 trillion by 2024

Takeaways from the State of the Global Islamic Economy Report 2020/21 will be unveiled at Reimagine: Halal in Asia 2020,...

gbafNews28 gbafNews28
News47 mins ago

Infor Launches Hospitality Management Cloud Solution based on Amazon Web Services in China to Spur Digital Transformation among Chinese Hotels

Rich capabilities allow hoteliers to centralize cross-platform hospitality management systems; AWS partnership ensures stability and security of data in the...